{"disease":{"id":"non-medullary-thyroid-cancer","name":"non medullary thyroid cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01109420","title":"Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT07259304","title":"Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT05675605","title":"A Study of TY-1091 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":248,"lead_sponsor_name":"TYK Medicines, Inc","has_results":false},{"nct_id":"NCT05278364","title":"Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":184,"lead_sponsor_name":"Shouyao Holdings (Beijing) Co. LTD","has_results":false},{"nct_id":"NCT04161391","title":"Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Turning Point Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04204928","title":"Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03906331","title":"Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Eli Lilly and Company","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}